e-Participation for the Guideline on Biopharmaceutics Classification System-Based Biowaivers
As part of the Drug Safety Center’s commitment to promoting transparent and inclusive regulatory processe.DSC announces launch of a public consultation on the document titled “Guideline on Biopharmaceutics Classification System-Based Biowaivers” through the e-Health Portal. The consultation aims to gather public feedback and comments on the guideline to help ensure the clarity and comprehensiveness of its content.
-
To collect opinions and feedback from stakeholders.
-
To ensure the comprehensiveness of the guideline.
-
To enhance transparency and accountability in policy development.
-
To strengthen trust between the regulatory authority and the public.
-
To ensure alignment with international best practices
Drug Safety Center invites all citizens, residents, and health sector stakeholders to submit their comments and suggestions on the guideline from 11 March 2026 to 11 April 2026.
Link for Submitting Feedback and Comments Click Here